- Home
- BDTX vs NYXH Comparison
BDTX vs NYXH Comparison
Compare BDTX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- NYXH
- Stock Information
- Founded
- BDTX 2014
- NYXH 2009
- Country
- BDTX United States
- NYXH Belgium
- Employees
- BDTX N/A
- NYXH N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- NYXH Medical/Dental Instruments
- Sector
- BDTX Health Care
- NYXH Health Care
- Exchange
- BDTX Nasdaq
- NYXH Nasdaq
- Market Cap
- BDTX 220.3M
- NYXH 188.1M
- IPO Year
- BDTX 2020
- NYXH 2021
- Fundamental
- Price
- BDTX $3.84
- NYXH $4.47
- Analyst Decision
- BDTX Strong Buy
- NYXH Strong Buy
- Analyst Count
- BDTX 6
- NYXH 3
- Target Price
- BDTX $10.17
- NYXH $12.67
- AVG Volume (30 Days)
- BDTX 1.1M
- NYXH 38.6K
- Earning Date
- BDTX 11-06-2025
- NYXH 11-13-2025
- Dividend Yield
- BDTX N/A
- NYXH N/A
- EPS Growth
- BDTX N/A
- NYXH N/A
- EPS
- BDTX 0.38
- NYXH N/A
- Revenue
- BDTX $70,000,000.00
- NYXH $6,616,215.00
- Revenue This Year
- BDTX N/A
- NYXH $85.62
- Revenue Next Year
- BDTX N/A
- NYXH $320.09
- P/E Ratio
- BDTX $10.20
- NYXH N/A
- Revenue Growth
- BDTX N/A
- NYXH 10.96
- 52 Week Low
- BDTX $1.20
- NYXH $4.35
- 52 Week High
- BDTX $4.94
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- BDTX 46.51
- NYXH 37.54
- Support Level
- BDTX $3.67
- NYXH $4.41
- Resistance Level
- BDTX $4.06
- NYXH $4.75
- Average True Range (ATR)
- BDTX 0.32
- NYXH 0.28
- MACD
- BDTX -0.06
- NYXH -0.07
- Stochastic Oscillator
- BDTX 13.95
- NYXH 9.93
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.